Sign In
Buy AVDL
$21.64
+0 (+0%)
At Close: May 08, 2026
Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results
07:00am, Monday, 03'rd Mar 2025
-- LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line with preliminary results published January 8 -- Reite
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3
04:05pm, Monday, 24'th Feb 2025
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host
Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales
08:00am, Monday, 24'th Feb 2025
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman ha
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 20'th Feb 2025
DUBLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of
Avadel Pharmaceuticals: Moving To A Speculative Buy
06:08pm, Tuesday, 11'th Feb 2025
Avadel Pharmaceuticals' primary asset, LUMRYZ, treats narcolepsy and is in Phase 3 trials for Idiopathic Hypersomnia, with significant revenue growth potential. Recent news includes the resignation of
ASL Strategic Value Fund Letter to Avadel Pharmaceuticals (AVDL: NASDAQ) Board of Directors
09:00am, Monday, 10'th Feb 2025
CHESTERFIELD, Mo.--(BUSINESS WIRE)--The following is a letter that ASL Strategic Value Fund sent to the Board of Directors of Avadel Pharmaceuticals (NASDAQ:AVDL): February 10, 2025 Mr. Geoff Glass Ch
There May Still Be Time to Get in on These 3 Trending Biotechs
08:15am, Monday, 20'th Jan 2025
Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed's first rate cut in several years in Septe
3 Oversold Biotech Names
12:56pm, Monday, 13'th Jan 2025
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens t
Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook
03:26am, Sunday, 12'th Jan 2025
Avadel Pharmaceuticals' 2025 net sales guidance for Lumryz was significantly below expectations due to increasing patient attrition. The company is increasing efforts to address some of these challeng
Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch
04:15pm, Wednesday, 08'th Jan 2025
-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 pat
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 06'th Jan 2025
DUBLIN, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of
DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
08:00am, Wednesday, 13'th Nov 2024
DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of m
Avadel Pharmaceuticals plc (AVDL) Q3 2024 Earnings Call Transcript
03:19pm, Tuesday, 12'th Nov 2024
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Austin Murtagh - Director, Precision AQ Greg Divis - CEO Richard Kim - CCO
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation
07:00am, Thursday, 31'st Oct 2024
DUBLIN, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that yesterday, the U.S
